The testing of a possible antibody treatment for COVID-19 by drug giant Eli Lilly has been put on hold over a “potential safety concern,’’ a report said Tuesday.
Officials involved in the government-sponsored, late-stage clinical trials e-mailed testing researchers saying the program had been halted because a participant fell ill, according to the New York Times.
“Safety is of the utmost importance to Lilly,’’ company rep Molly McCully wrote The Post in an e-mail Tuesday.
“We are aware that, out of an abundance of caution, the ACTIV-3 independent data safety monitoring board (DSMB) has recommended a pause in enrollment,’’ the rep said, referring to the group of clinical-research experts that helps the government oversee such trials.
“The trial, evaluating Lilly’s investigational neutralizing antibody as a treatment for COVID-19 in hospitalized patients, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH),’’ McCully said.
“Lilly is supportive of the decision